vs
Side-by-side financial comparison of Axil Brands, Inc. (AXIL) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $8.1M, roughly 2.0× Axil Brands, Inc.). Axil Brands, Inc. runs the higher net margin — 8.7% vs -7.8%, a 16.4% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 5.2%). Over the past eight quarters, Axil Brands, Inc.'s revenue compounded faster (12.1% CAGR vs 11.0%).
Axil Brands, Inc. is a U.S.-headquartered company that designs, manufactures and markets premium hearing protection products, audio enhancement devices and personal audio accessories. Its offerings include custom-fit earplugs, Bluetooth-enabled hearing buds for work, sports and leisure use, serving both consumer and professional segments across global markets.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
AXIL vs DERM — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $8.1M | $16.1M |
| Net Profit | $704.9K | $-1.2M |
| Gross Margin | 68.1% | — |
| Operating Margin | 11.1% | -2.8% |
| Net Margin | 8.7% | -7.8% |
| Revenue YoY | 5.2% | 27.3% |
| Net Profit YoY | 11.2% | -182.0% |
| EPS (diluted) | $0.09 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $8.1M | $16.1M | ||
| Q3 25 | $6.9M | $17.0M | ||
| Q2 25 | $5.8M | $15.0M | ||
| Q1 25 | $6.9M | $13.1M | ||
| Q4 24 | $7.7M | $12.6M | ||
| Q3 24 | $5.9M | $14.6M | ||
| Q2 24 | $6.5M | $14.9M | ||
| Q1 24 | $6.5M | $13.0M |
| Q4 25 | $704.9K | $-1.2M | ||
| Q3 25 | $334.3K | $-2.3M | ||
| Q2 25 | $-245.6K | $-3.8M | ||
| Q1 25 | $576.7K | $-4.1M | ||
| Q4 24 | $633.7K | $1.5M | ||
| Q3 24 | $-109.8K | $-2.4M | ||
| Q2 24 | $49.5K | $-3.4M | ||
| Q1 24 | $781.1K | $-10.4M |
| Q4 25 | 68.1% | — | ||
| Q3 25 | 67.6% | — | ||
| Q2 25 | 70.0% | — | ||
| Q1 25 | 71.7% | — | ||
| Q4 24 | 71.1% | 82.3% | ||
| Q3 24 | 71.0% | 63.9% | ||
| Q2 24 | 71.5% | 56.0% | ||
| Q1 24 | 71.5% | 47.7% |
| Q4 25 | 11.1% | -2.8% | ||
| Q3 25 | 6.0% | -9.0% | ||
| Q2 25 | 0.8% | -19.2% | ||
| Q1 25 | 8.4% | -25.3% | ||
| Q4 24 | 8.7% | 17.7% | ||
| Q3 24 | -2.4% | -19.8% | ||
| Q2 24 | 2.6% | -19.7% | ||
| Q1 24 | -1.6% | -77.4% |
| Q4 25 | 8.7% | -7.8% | ||
| Q3 25 | 4.9% | -13.6% | ||
| Q2 25 | -4.3% | -25.3% | ||
| Q1 25 | 8.3% | -31.0% | ||
| Q4 24 | 8.2% | 12.1% | ||
| Q3 24 | -1.9% | -16.3% | ||
| Q2 24 | 0.8% | -22.6% | ||
| Q1 24 | 12.1% | -80.1% |
| Q4 25 | $0.09 | $-0.04 | ||
| Q3 25 | $0.04 | $-0.09 | ||
| Q2 25 | $-0.03 | $-0.16 | ||
| Q1 25 | $0.07 | $-0.18 | ||
| Q4 24 | $0.08 | $0.10 | ||
| Q3 24 | $-0.02 | $-0.12 | ||
| Q2 24 | $0.11 | $-0.17 | ||
| Q1 24 | $0.04 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.0M | $24.1M |
| Total DebtLower is stronger | $138.3K | $25.3M |
| Stockholders' EquityBook value | $11.1M | $31.9M |
| Total Assets | $16.2M | $94.6M |
| Debt / EquityLower = less leverage | 0.01× | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.0M | $24.1M | ||
| Q3 25 | $4.1M | $24.9M | ||
| Q2 25 | $4.8M | $20.3M | ||
| Q1 25 | $4.7M | $21.1M | ||
| Q4 24 | $5.2M | $20.3M | ||
| Q3 24 | $4.1M | $22.5M | ||
| Q2 24 | $3.3M | $23.9M | ||
| Q1 24 | $4.9M | $24.1M |
| Q4 25 | $138.3K | $25.3M | ||
| Q3 25 | $139.2K | $25.2M | ||
| Q2 25 | $140.2K | $25.1M | ||
| Q1 25 | $141.0K | $25.0M | ||
| Q4 24 | $143.3K | $24.9M | ||
| Q3 24 | $144.3K | $19.8M | ||
| Q2 24 | $146.6K | $19.7M | ||
| Q1 24 | — | $14.7M |
| Q4 25 | $11.1M | $31.9M | ||
| Q3 25 | $10.2M | $25.9M | ||
| Q2 25 | $9.7M | $19.2M | ||
| Q1 25 | $9.7M | $21.5M | ||
| Q4 24 | $8.8M | $20.1M | ||
| Q3 24 | $7.9M | $10.9M | ||
| Q2 24 | $7.7M | $11.3M | ||
| Q1 24 | $8.8M | $13.0M |
| Q4 25 | $16.2M | $94.6M | ||
| Q3 25 | $15.4M | $85.2M | ||
| Q2 25 | $12.9M | $81.2M | ||
| Q1 25 | $13.0M | $85.0M | ||
| Q4 24 | $13.7M | $80.2M | ||
| Q3 24 | $11.4M | $64.0M | ||
| Q2 24 | $11.0M | $65.2M | ||
| Q1 24 | $12.7M | $66.6M |
| Q4 25 | 0.01× | 0.79× | ||
| Q3 25 | 0.01× | 0.97× | ||
| Q2 25 | 0.01× | 1.30× | ||
| Q1 25 | 0.01× | 1.16× | ||
| Q4 24 | 0.02× | 1.24× | ||
| Q3 24 | 0.02× | 1.81× | ||
| Q2 24 | 0.02× | 1.75× | ||
| Q1 24 | — | 1.13× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $934.8K | $-6.3M |
| Free Cash FlowOCF − Capex | $906.4K | — |
| FCF MarginFCF / Revenue | 11.1% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | 1.33× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $934.8K | $-6.3M | ||
| Q3 25 | $-739.2K | $-2.4M | ||
| Q2 25 | $194.4K | $-942.0K | ||
| Q1 25 | $-169.9K | $-2.8M | ||
| Q4 24 | $1.0M | $2.2M | ||
| Q3 24 | $897.3K | $-1.2M | ||
| Q2 24 | $-336.6K | $-5.2M | ||
| Q1 24 | $-912.8K | $-5.0M |
| Q4 25 | $906.4K | — | ||
| Q3 25 | $-747.6K | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $-258.2K | — | ||
| Q4 24 | $941.1K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-394.9K | — | ||
| Q1 24 | $-922.1K | — |
| Q4 25 | 11.1% | — | ||
| Q3 25 | -10.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -3.7% | — | ||
| Q4 24 | 12.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -6.1% | — | ||
| Q1 24 | -14.3% | — |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 0.9% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.9% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | 1.33× | — | ||
| Q3 25 | -2.21× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.29× | — | ||
| Q4 24 | 1.59× | 1.46× | ||
| Q3 24 | — | — | ||
| Q2 24 | -6.80× | — | ||
| Q1 24 | -1.17× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXIL
| Hearing Enhancement And Protection | $7.8M | 95% |
| Other | $378.9K | 5% |
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
